Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05553496
Other study ID # PHCL555
Secondary ID
Status Not yet recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date September 25, 2022
Est. completion date October 1, 2023

Study information

Verified date September 2022
Source Ain Shams University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Prospective interventional comparative study to compare the efficacy of Rituximab versus Conventional treatment in Refractory Nephrotic Syndrome including patients on triple immunosuppression protocols.


Description:

A prospective randomized controlled interventional study, conducted on Refractory Nephrotic syndrome patients with failed different lines of conventional treatment. The aim of the current study is to assess the therapeutic response of Rituximab versus Conventional treatment in Refractory Nephrotic Syndrome in terms of : - Improvement in proteinuria. - Relapse frequency. Fourty patients with Refractory Nephrotic syndrome will be enrolled in the study. All participants will be previously treated with ACEi and/or ARB, for ≥3 months prior to randomization and adequate blood pressure control. Participants will be assigned randomly into two groups with 20 Refractory Nephrotic syndrome patients in each group as follow: - Group (1) RTX in Refractory Nephrotic syndrome patients on conventional treatment (20 patients) - Group (2) Refractory Nephrotic Syndrome patients on Conventional therapy (20 patients) The duration and severity of proteinuria are known to be surrogate markers of the progression of glomerular disease. Our approach to assess the clinical response was to evaluate estimated Glomerular filtration rate (eGFR), proteinuria and serum albumin after rituximab treatment. We classified the response into four stages : 1. No proteinuria, normal serum albumin 2. Mild proteinuria, serum albumin >30 g/l 3. Ongoing significant proteinuria, serum albumin 20-30 g/l 4. No change in proteinuria and serum albumin. Stages 1 and 2 will be interpreted as a good clinical response, whereas stages 3 and 4 will be interpreted as a poor clinical response. A sample size of fourty patients with Refractory Nephrotic syndrome is selected to achieve confidence limit of 5%. At the end of the study, a number of data will be generated, such as: 1. Quantitative data will be summarized as means and standard deviations and/or medians and ranges. 2. Categorical data will be summarized as frequencies & percentage. 3. For measuring statistical differences between groups, categorical variables are analyzed using the chi-squared test or Fisher's exact test, whereas continuous variables are compared using Student t tests or Mann-Whitney U tests or Wilcoxon signed-rank test, as appropriate. 4. Statistical comparisons between pre- and post-treatment values are performed using the Wilcoxon signed-rank test. 5. Univariate linear regression models are used to examine the association between baseline characteristics and response to drug treatment. 6. All tests are performed at a significance level of 0.05.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date October 1, 2023
Est. primary completion date April 1, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Adult = 18 year old and medically stable. 2. Treatment with an Angiotension converting enzyme inhibitor (ACEi) and/or Angiotension II receptor blockade (ARB), for =3 months prior to randomization and adequate blood pressure control or if patient is intolerant to even a very low dose of either ACEi or ARB therapy. 3. Proteinuria =3 g/24 h using the average from two 24-hour urine collections collected within 14 days of each other despite ARB for =3 months as described above. 4. Estimated GFR =40 ml/min/1.73 m2 while taking ACEi/ARB therapy or quantified endogenous creatinine clearance =40 ml/min based on a 24 h urine collection. 5. Non responsive GN patients on conventional treatment. Exclusion Criteria: 1. Autoimmune diseases. 2. Patients with presence of active infection or a secondary cause of IMN (e.g. hepatitis B, SLE, medications, malignancies). 3. Type 1 or 2 diabetes mellitus: to exclude proteinuria secondary to diabetic nephropathy. 4. Pregnancy or breast feeding. 5. Predisposition to drug hypersensitivity. 6. Unstable medical condition.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Rituximab
Group (1) RTX in Refractory Nephrotic syndrome patients on conventional treatment (20 patients)
Dexamethasone
Group (2) Refractory Nephrotic Syndrome patients on Conventional therapy (20 patients)

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Ain Shams University

Outcome

Type Measure Description Time frame Safety issue
Primary The effectiveness of either conventional therapy alone or Rituximab as an add on therapy will be assessed by measure of Remission sate of the patient. The primary end point is Complete or Partial remission at 6 months after randomization. Complete remission (CR) is defined as UP =0.3 g/24 h and serum albumin =3.5 g/dl while Partial remission (PR) is defined as Reduction in baseline UP of =50% plus final UP =3.5 g/24 h but >0.3 g/24 h. The patient who will be Non-responsive to therapy is defined as Reduction in baseline UP of <25% (includes increase in UP) after 6 months of immunosuppression and the patient who will enter in the relapsed phase is defined as development of nephrotic range proteinuria following CR or PR, i.e. >3.5 g/24 h. 6 months
Secondary A) Late Remissions: The first 6 months of the study will be considered the treatment period, while the remaining 6 months will be considered an observational period.So we will monitor the patients for CR or PR at 6, 9, and 12 months after randomization. 6, 9, and 12 months after randomization.
Secondary B) Relapse state: Relapse state of the patient will be assessed at month 12 after randomization (Urine Protein (UP) >3.5 g/24 h after earlier CR or PR). 12 months after randomization
Secondary C) Response Treatment Time: The response time will be assessed by measuring the duration of clinical response to RTX in patients who had on going CR or PR. 12 months after randomization
Secondary D) End Stage Renal Disease (ESRD): The patients who developed ESRD will be reviewed in this study. 12 months after randomization
Secondary E) Renal Function: The effect of treatment on renal function will be assessed every 3 months by calculating the estimated GFR (eGFR) with the creatinine-based Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula from baseline to 6 months. 6 months after randomization
Secondary F) Adverse events: Patients will be educated about adverse effects of the drugs and will be required to report the occurrence of any of them. 6, 9, and 12 months after randomization.
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06040853 - Postoperative Pain in Laparoscopic Radical Prostatectomy Surgery With Tranexamic Acid: Analgesia? Hiperalgesia? Phase 4
Recruiting NCT05534802 - Ulinastatin Improves and Prevents Cardiac Dysfunction Induced by Cardiopulmonary Bypass N/A
Recruiting NCT04190537 - PARADOX - the Incidence of Paradoxical Reactions in Pediatric Patients Premedicated With Midazolam
Completed NCT03522532 - Dental Restorations Effect on Oxidative Status of the Gingival Crevicular Fluid N/A
Completed NCT03119454 - "Corticoid-16" in Long Term When Administered Systemically in Patients in Routine Medical Practice N/A
Unknown status NCT01614353 - Medication-taking Preferences & Practices of Patients With Chronic Conditions N/A
Completed NCT03714360 - The Effect of Tranexamic Acid. A Randomised Study of Patients Undergoing Elective Lumbar Spine Surgery. Phase 4
Recruiting NCT03352622 - Pharmacogenomic in Colombian Patients With Rheumatoid Arthritis N/A
Recruiting NCT06288841 - Efficacy and Safety of Liposomal Bupivacaine Under ERAS Concept for Postoperative Analgesia of Ultrasound-Guided QLB in Gynecologic Laparoscopic Patients: A Randomized, Single-blind, Active-Controlled Clinical Study N/A
Not yet recruiting NCT04320277 - Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study. Phase 2/Phase 3
Completed NCT03359590 - Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients Phase 2
Completed NCT05591105 - Morphine Consumption in the Obese Patients
Not yet recruiting NCT03904303 - Test of a New Gel-based Colon Cleansing Agent Compared to Moviprep Phase 1
Not yet recruiting NCT05453045 - Pharmacokinetics and Excretion of Albendazole and Its Metabolites in Saliva N/A
Completed NCT05428683 - Intravitreal Triamcinolone and Moxifloxacin Injection After Cataract Surgery N/A
Enrolling by invitation NCT02985281 - Safety and Efficacy of Gratisovir (Sofosbuvir)- Ribavirin Therapy in Pediatric Patients Phase 2/Phase 3
Recruiting NCT06222710 - Ultrasound Guiding Pharmacopuncture Therapy for Supraspinatus Tendinopathy N/A
Not yet recruiting NCT03953287 - Pharmacokinetic Study of Paracetamol. Phase 1
Recruiting NCT03622047 - Comparison of Epidural Labor Analgesia With Dexmedetomidine or Sufentanil N/A
Active, not recruiting NCT06324370 - Exploratory Pharmacokinetic Study of Virgin Coconut Oil (VCO) N/A